Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 19/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12943220 | 0.92 | ADORA1 (0.51) | ADORA1KDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL12907883 | 0.89 | ADORA1 (0.55) | ADORA1SLC6A3 | |
| SCHEMBL923720 | 0.81 | ADORA1 (0.65) | ADORA1SLC6A3 | |
| SCHEMBL12907888 | 0.81 | ADORA1 (0.54) | ADORA1SLC6A3 | |
| SCHEMBL12907808 | 0.79 | CHEK1 (0.41) | ADORA1KDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL12907885 | 0.79 | ADORA1 (0.60) | ADORA1 | |
| SCHEMBL12907866 | 0.78 | ADORA1 (0.60) | ADORA1SLC6A3 | |
| SCHEMBL12907880 | 0.78 | ADORA1 (0.47) | ADORA1SLC6A3 | |
| SCHEMBL12907876 | 0.77 | ADORA1 (0.44) | ADORA1KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL12907877 | 0.74 | ADORA1 (0.46) | ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021487-A1 | CYCLOALKOXY-SUBSTITUTED 4-PHENYL-3,5-DICYANOPYRIDINES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021487-A1 | CYCLOALKOXY-SUBSTITUTED 4-PHENYL-3,5-DICYANOPYRIDINES AND THEIR USE | PC, DPP4, FABP3 | ADORA1 3492/4885KDM4E 1690/4885USP2 3619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.